CytRx reports positive interim results By: MarketMinute.com Stock News January 06, 2015 at 13:32 PM EST CytRx Corp. (Nasdaq: CYTR) reported positive interim results from a Phase 2 study of aldoxorubicin to treat brain cancer lifting the stock price 57 cents to $3.42.